Kura Oncology (KURA) Stock Price, Quote & News

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC;...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 500 8800

Website: kuraoncology.com

Address:

12730 High Bluff Drive, Suite 400, San Diego, United States

Olena Oct. 25 at 8:28 PM

$KURA it should move up towards fda in November. Hope to $16 before fda decision

0 · Reply

CharlieeMungerTWITS Oct. 25 at 12:28 PM

$KURA lol. I used some extra powder to make a quick $2300 on this weeks dip. Sure, ain’t much but the aggregate EOY pays for my lake house

1 · Reply

saddy12345 Oct. 25 at 9:53 AM

$KURA Kura Oncology CEO Troy Edward Wilson bought shares in September 2025, acquiring 50,000 shares for approximately $410,145. He also sold 36,615 shares in late September 2025 for about $327,418 to cover taxes, according to MarketBeat and Investing.com. September 2025 Purchase: Wilson bought 50,000 shares at a weighted average price of about $8.20 per share. September 2025 Sale: He sold 36,615 shares for approximately $327,418. Reason for Sale: The sale was to cover taxes on performance-based restricted stock units that had vested.

0 · Reply

Klemmer777 Oct. 25 at 8:57 AM

$KURA Tell me your salty about selling early without saying you’re salty about selling early😂

1 · Reply

LiquidThetaLEAPS Oct. 25 at 2:32 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $KURA Current Share Price: $9.18 Contracts: $KURA April 17, 2026 $10 Calls Scale in: $2.80- $3.42 Scale out: $4.36-$5.60 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

MikeJonesSwishaHouse Oct. 24 at 11:07 PM

$KURA what am I missing here? ~ 600m in cash. Why are they so undervalued?

0 · Reply

roquefort Oct. 24 at 10:41 PM

$KURA Seems like a derisking event to me. Hoping for $15 in runup to PDUFA.

0 · Reply

JFais Oct. 24 at 9:54 PM

$SNDX- Don't want to be a single stock poster, but will share a few more nuggets from the call as people asking for it: ***Usual caveats (am a Wall Street Nobody), but think bears/skeptics are missing forest for the trees -ONLY menin inhibitor with positive pivotal data in children, allowing for indication to treat patients 1 year of age or older -NPM1m AML pivotal data surpasses that seen for any other menin inhibitor across multiple efficacy measures (pot shot at $KURA and big pharma behind them) including on ORR, transplant rate, CR/CRh and median OS among responders. Particularly notable is 47% ORR and 11% transplant rate following Revuforj treatment. -While CR/CRc is key regulatory measure, ORR is key from a clinical standpoint (higher ORR gives clinicians ability to get more patients to remission and the best chance of bringing their eligible patients to potentially curative stem cell transplant)

1 · Reply

ConfidencePotato Oct. 24 at 9:36 PM

$KURA Cantor Fitzgerald raised their KURA approval probability from 45% to 75% following deal diligence, while industry benchmarks suggest Breakthrough Therapy Designation confers 60-70% baseline probability. The current consensus probability is 65-75%, factoring in SNDX’s validation of the menin inhibitor mechanism, NPM1-mutant AML as a viable indication, and acceptable risk-benefit profiles for this desperate patient population.

1 · Reply

outlawinvestor1 Oct. 24 at 7:51 PM

$KURA $SNDX hmmmm... @dgbio

0 · Reply

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Oct 18, 2025, 6:56 PM EDT - 6 days ago

Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript

Oct 18, 2025, 3:23 AM EDT - 7 days ago

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 3, 2025, 7:30 AM EDT - 22 days ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2025, 5:02 PM EDT - 23 days ago

Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 7:01 AM EDT - 24 days ago

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Sep 29, 2025, 4:01 PM EDT - 26 days ago

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

$Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology$

Sep 25, 2025, 5:18 PM EDT - 4 weeks ago

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Sep 24, 2025, 7:30 AM EDT - 4 weeks ago

Kura Oncology to Participate in Upcoming Investor Conference

Sep 19, 2025, 11:03 AM EDT - 5 weeks ago

Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy

Sep 16, 2025, 10:53 PM EDT - 5 weeks ago

Kura Oncology, Inc. - Special Call

Sep 16, 2025, 4:01 PM EDT - 5 weeks ago

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Sep 10, 2025, 4:44 PM EDT - 6 weeks ago

Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 3, 2025, 8:02 AM EDT - 7 weeks ago

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Aug 28, 2025, 7:30 AM EDT - 2 months ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Aug 9, 2025, 10:46 PM EDT - 2 months ago

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Kura Oncology Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Kura Oncology to Report Second Quarter 2025 Financial Results

Jul 2, 2025, 12:09 AM EDT - 4 months ago

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Jun 12, 2025, 7:30 AM EDT - 4 months ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Jun 2, 2025, 6:00 PM EDT - 5 months ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

$Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML$

Jun 1, 2025, 7:00 PM EDT - 5 months ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

May 22, 2025, 5:30 PM EDT - 5 months ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 14, 2025, 10:00 AM EDT - 5 months ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 6, 2025, 7:30 AM EDT - 6 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 1, 2025, 8:48 PM EDT - 6 months ago

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 6 months ago

Kura Oncology Reports First Quarter 2025 Financial Results

Apr 28, 2025, 7:30 AM EDT - 6 months ago

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Apr 24, 2025, 7:30 AM EDT - 6 months ago

Kura Oncology to Report First Quarter 2025 Financial Results

Apr 8, 2025, 7:30 AM EDT - 7 months ago

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Apr 1, 2025, 7:30 AM EDT - 7 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Mar 26, 2025, 7:30 AM EDT - 7 months ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Mar 4, 2025, 10:12 AM EST - 8 months ago

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Feb 27, 2025, 4:46 AM EST - 8 months ago

Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:03 PM EST - 8 months ago

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 7:30 AM EST - 8 months ago

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 6, 2025, 12:05 PM EST - 9 months ago

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

Feb 5, 2025, 4:01 PM EST - 9 months ago

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Jan 6, 2025, 4:30 PM EST - 10 months ago

Kura Oncology Announces Senior Executive Promotions

Dec 18, 2024, 1:46 PM EST - 11 months ago

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Dec 9, 2024, 7:00 AM EST - 11 months ago

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Dec 2, 2024, 7:30 AM EST - 11 months ago

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Nov 25, 2024, 7:30 AM EST - 11 months ago

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Nov 20, 2024, 5:52 PM EST - 1 year ago

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

Nov 20, 2024, 5:00 PM EST - 1 year ago

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Nov 9, 2024, 5:54 AM EST - 1 year ago

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 9:09 AM EST - 1 year ago

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Report Third Quarter 2024 Financial Results

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

Olena Oct. 25 at 8:28 PM

$KURA it should move up towards fda in November. Hope to $16 before fda decision

0 · Reply

CharlieeMungerTWITS Oct. 25 at 12:28 PM

$KURA lol. I used some extra powder to make a quick $2300 on this weeks dip. Sure, ain’t much but the aggregate EOY pays for my lake house

1 · Reply

saddy12345 Oct. 25 at 9:53 AM

0 · Reply

Klemmer777 Oct. 25 at 8:57 AM

$KURA Tell me your salty about selling early without saying you’re salty about selling early😂

1 · Reply

LiquidThetaLEAPS Oct. 25 at 2:32 AM

0 · Reply

MikeJonesSwishaHouse Oct. 24 at 11:07 PM

$KURA what am I missing here? ~ 600m in cash. Why are they so undervalued?

0 · Reply

roquefort Oct. 24 at 10:41 PM

$KURA Seems like a derisking event to me. Hoping for $15 in runup to PDUFA.

0 · Reply

JFais Oct. 24 at 9:54 PM

1 · Reply

ConfidencePotato Oct. 24 at 9:36 PM

1 · Reply

outlawinvestor1 Oct. 24 at 7:51 PM

$KURA $SNDX hmmmm... @dgbio

0 · Reply

JFais Oct. 24 at 7:50 PM

$KURA- keep in mind how this trades if there's a CMC-related CRL (one reason I took profits re r/r) Again, hopeful zifto gets approved as more options for patients= a Win (and I can revisit as a commercial-stage setup if "sell the news") Reminder CEO known for overpromising...

3 · Reply

PickleRick10 Oct. 24 at 7:34 PM

$SNDX no one here actually listened to the investor call. Company said VERY LOW rate of adverse effects and high efficacy, proven safety profile, and BETTER data than $KURA but will need to wait and see what their data says apparently

1 · Reply

Olena Oct. 24 at 7:21 PM

$SNDX load more on $KURA now! Next in line

1 · Reply

Candycaneispeppermint Oct. 24 at 7:12 PM

$KURA I bought in after sndx poor outcome and added more just now. Trial safety data just looks to clean. I am getting fomo but will pump the breaks and look for more entry over coming two weeks. I think this one is in a prime position.

0 · Reply

lowfloatscambuster Oct. 24 at 7:09 PM

$KURA Jury still out on $SNDX but the safety warning is nothing but positive for KURA given the better safety and tolerability profile.

0 · Reply

Gundragon Oct. 24 at 5:57 PM

$KURA doesnt look like its reacting too well..

2 · Reply

ConfidencePotato Oct. 24 at 5:46 PM

$KURA When sndx HALT lifts, we’ll know: • If M&A → KURA becomes even stronger hold • If offering → No impact on KURA thesis • If mystery good news → Probably bullish for sector

1 · Reply

GSD78626 Oct. 24 at 5:32 PM

$JNJ $KURA $SNDX

0 · Reply

JFais Oct. 24 at 5:31 PM

$SNDX (L) Last point: The fact that Revuforj was approved in patients 1 year and older really speaks to risk/benefit profile in the context of a devastating & rapidly progressing disease Even without frontline (assume big pharma $JNJ Kyowa/ $KURA et al beat them there) $1B + easily in r/r alone as treatment durations move up to 12 months + majority of docs use in maintenance setting post-transplant GLTA and have a great weekend

1 · Reply

blueb22 Oct. 24 at 5:30 PM

$KURA - SNDX received approval. That means Kura will get Zufto approval for sure (100%) and one time. So all good. And de-risked completely

0 · Reply

ConfidencePotato Oct. 24 at 5:25 PM

$KURA boom for the tech….. let’s see now if she reacts as expected.

0 · Reply

diegosan21 Oct. 24 at 5:24 PM

$SNDX let's see those gains $KURA

1 · Reply

Market Cap	789.85M
Revenue (ttm)	53.88M
Net Income (ttm)	-173.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-322.90%
Debt to Equity Ratio	0.03

Volume	2,869,600
Avg Vol	1,860,448
Day's Range	N/A - N/A
Shares Out	86.80M
Stochastic %K	41%
Beta	0.32
Analysts	Strong Sell
Price Target	$27.00